PTTG1IP and breast cancer: A particularly convincing survival difference was observed for patients of all breast cancer subtypes between the most favourable (high PTTG1IP and low securin) and the most unfavourable (low PTTG1IP and high securin) outcome of the disease (Fig. 3b).